BioSpace News Archive

The global foot and mouth disease vaccines market is foreseen to attain growth as vaccination is considered to be a basic yet important initiative undertaken to curb animal loss.

According to Transparency Market Research’s latest report on the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of cystic fibrosis and chronic pancreatitis to escalate the growth of global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market.

Pharmaceutical industry is progressing at a rapid rate to cover the various diseases that affect human beings.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that it will host a virtual R&D Day on 06 November 2020 from 13.00 CET.

Save the date for Swedish Orphan Biovitrum AB Capital Markets Day on 10 December 2020.

PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will participate in the 26th Annual International BIO-Europe Partnering Conference which will be held digitally from October 26th to 29th.

- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, provided preliminary unaudited revenue estimates for the third quarter ended September 30, 2020 , in conjunction with proposed debt refinancing tran

INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treatedwith a platinum-based therapy and PD-(L)1 inhibitor

New test enables “in your own lab” sample-to-report workflow that detects and quantifies >6,000 microbial strains in under 30 hours.

Milestone Pharmaceuticals Inc. announced the pricing of its previously announced underwritten public offering of 3,810,097 of its common shares, and to certain investors in lieu thereof, pre-funded warrants to purchase 4,761,903 of its common shares at an exercise price of $0.01 per share.